

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA, 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 04-11-2019	2. REPORT TYPE Final Report	3. DATES COVERED (From - To) 24-Oct-2012 - 23-Oct-2017
---	--------------------------------	---

4. TITLE AND SUBTITLE Final Report: Section II, A 1 (ARL) g. Research Area 7: Chemical Sciences	5a. CONTRACT NUMBER W911NF-13-1-0006
	5b. GRANT NUMBER
	5c. PROGRAM ELEMENT NUMBER 611102

6. AUTHORS	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAMES AND ADDRESSES North Carolina State University 2701 Sullivan Drive Admin Srvcs III, Box 7514 Raleigh, NC 27695 -7514	8. PERFORMING ORGANIZATION REPORT NUMBER
--	--

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS (ES) U.S. Army Research Office P.O. Box 12211 Research Triangle Park, NC 27709-2211	10. SPONSOR/MONITOR'S ACRONYM(S) ARO
	11. SPONSOR/MONITOR'S REPORT NUMBER(S) 63035-ST.1

12. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.
--

13. SUPPLEMENTARY NOTES The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation.

14. ABSTRACT

15. SUBJECT TERMS

16. SECURITY CLASSIFICATION OF:	17. LIMITATION OF ABSTRACT	15. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Matthew Breen
a. REPORT UU	b. ABSTRACT UU	c. THIS PAGE UU	19b. TELEPHONE NUMBER 919-513-1467

RPPR Final Report
as of 06-Nov-2019

Agency Code:

Proposal Number: 63035ST

Agreement Number: W911NF-13-1-0006

INVESTIGATOR(S):

Name: Ph.D. Matthew Breen
Email: matthew_breen@ncsu.edu
Phone Number: 9195131467
Principal: Y

Organization: **North Carolina State University**

Address: 2701 Sullivan Drive, Raleigh, NC 276957514

Country: USA

DUNS Number: 042092122

EIN: 566000756

Report Date: 23-Nov-2017

Date Received: 04-Nov-2019

Final Report for Period Beginning 24-Oct-2012 and Ending 23-Oct-2017

Title: Section II, A 1 (ARL) g. Research Area 7: Chemical Sciences

Begin Performance Period: 24-Oct-2012

End Performance Period: 23-Oct-2017

Report Term: 0-Other

Submitted By: Paul Reid

Email: paul.r.reid.ctr@mail.mil

Phone: (919) 549-4333

Distribution Statement: 1-Approved for public release; distribution is unlimited.

STEM Degrees:

STEM Participants:

Major Goals: The specific objectives of the MWD Genomics Program are best describes as two phases. In Phase-I (the current study) we will gather information and data from the S&T community, handlers and breeders. In addition we will identify additional individuals/institutions able to contribute to the broader goals of Phase-II. Phase-I also will include the initiation of a MWD DNA bank and use of these to provide a preliminary assessment of breed ancestry of select MWDs. As Phase-I is conducted, the data obtained will be used to provide the foundations for Phase-II, a large scale experimental genomics initiative, using state of the art technologies to address key needs of the MWD Program and advance the overall goals of the Future Combat Canine Research Program (FCCRP).

Accomplishments: Phase-I of this program effort was restricted to two key areas

- 1) information gathering
- 2) introductory genetic assessment of breed ancestry in current MWDs.

Information gathering

During the third year of this project, Dr. Breen continued to meet with the contracting office representative (COR), Dr. Stephen Lee, to provide regular updates on progress. During this time period we continued to identify and build relationships with individuals and institutions likely to play an active role as key stakeholders in Phase II of the program. Meetings were coordinated with each of the individuals/institutions across the USA, during which the overall goals of the MWD Genomics Program were discussed and interest of the third parties gauged. The results of these meeting was the enthusiastic support of numerous individuals, as well three large US corporations (names withheld for confidentiality). The role that each of these additional individuals/groups will play in the larger program is part of ongoing discussions.

Introductory genetic assessment of breed ancestry in current MWDs

In advance of the major experimental phase of this program we continued to recruit and bank blood and DNA samples from additional MWDs. Each of the dogs recruited had been assessed for key performance metrics in readiness for convergence with the genetic/genomic data. By the end of this study we had recruited blood samples from over 200 MWDs, representing two large cohorts with specific purpose. From each blood sample, genomic DNA was isolated and used for a first pass single nucleotide polymorphism (SNP) screen to determine breed lineage. These data indicated that while the majority of the 200 dogs recruited to date were of single breed lineage (Labrador retriever, German Shepherd and Belgian Malinois), several dogs were mixed breed with one of these three breeds as the major component. These DNA samples have been set aside for use in future case-control studies designed to identify haplotypes associated with specific traits key to their purpose.

RPPR Final Report as of 06-Nov-2019

In Year 3 we met with a panel of key opinion leaders in the canine genetics community to contribute to the design of a new higher density SNP set. The goal of this new higher density (HD) platform was to provide an improved means to generate genome wide association data for more complex traits, such as behavior. Through several discussion among the group, we selected 1,104,936 high quality SNPs from over 19,000,000 SNPs that had been identified from over 350 whole canine genome sequences. The SNPs selected were those with the highest level of polymorphism across numerous dog breeds, including breeds that are primary contributors to the MWD population. With a SNP located every 2,200 bp across the entire canine genome, this new set offers 6x the density of the initial design, while simultaneously increasing the number of informative SNPs across breeds from ~55% to ~85%. In short, this new canine SNP set has the potential to provide a substantially greater ability to detect genetic variants associated with complex traits.

The implementation of this new canine HD-design will require funding beyond the current award. At this time the additional funding needed will be used to demonstrate the efficacy of this new genetics platform. We anticipate that these fund will be provided by consortium members. It is expected that access to this new SNP-platform will be made broadly available to canine genetic researchers with the expectation that data will be shared as a means to validate the utility of this new design.

Training Opportunities: Nothing to Report

Results Dissemination: Nothing to Report

Honors and Awards: Nothing to Report

Protocol Activity Status:

Technology Transfer: Nothing to Report

PARTICIPANTS:

Participant Type: PD/PI

Participant: Matthew Breen

Person Months Worked: 12.00

Project Contribution:

International Collaboration:

International Travel:

National Academy Member: N

Other Collaborators:

Funding Support:

Funding W911NF1310006.

FINAL REPORT

- **Specific Objectives**

The specific objectives of the MWD Genomics Program are best describes as two phases. In Phase-I (the current study) we will gather information and data from the S&T community, handlers and breeders. In addition we will identify additional individuals/institutions able to contribute to the broader goals of Phase-II. Phase-I also will include the initiation of a MWD DNA bank and use of these to provide a preliminary assessment of breed ancestry of select MWDs. As Phase-I is conducted, the data obtained will be used to provide the foundations for Phase-II, a large scale experimental genomics initiative, using state of the art technologies to address key needs of the MWD Program and advance the overall goals of the Future Combat Canine Research Program (FCCRP).

Note: This award provided funding only for a proportion of Dr. Breen's time (0.2x FTE) and so all experimental data for the generation and use of the new genetics platform are being developed with funds outside the scope of this award.

- **Results**

Phase-I of this program effort was restricted to two key areas

- 1) information gathering
- 2) introductory genetic assessment of breed ancestry in current MWDs.

Information gathering

During the third year of this project, Dr. Breen continued to meet with the contracting office representative (COR), Dr. Stephen Lee, to provide regular updates on progress. During this time period we continued to identify and build relationships with individuals and institutions likely to play an active role as key stakeholders in Phase II of the program. Meetings were coordinated with each of the individuals/institutions across the USA, during which the overall goals of the MWD Genomics Program were discussed and interest of the third parties gauged. The results of these meeting was the enthusiastic support of numerous individuals, as well three large US corporations (names withheld for confidentiality). The role that each of these additional individuals/groups will play in the larger program is part of ongoing discussions.

Introductory genetic assessment of breed ancestry in current MWDs

In advance of the major experimental phase of this program we continued to recruit and bank blood and DNA samples from additional MWDs. Each of the dogs recruited had been assessed for key performance metrics in readiness for convergence with the genetic/genomic data. By the end of this study we had recruited blood samples from over 200 MWDs, representing two large cohorts with specific purpose. From each blood sample, genomic DNA was isolated and used for a first pass single nucleotide polymorphism (SNP) screen to determine breed lineage. These data indicated that while the majority of the 200 dogs recruited to date were of single breed lineage (Labrador retriever, German Shepherd and Belgian Malinois), several dogs were mixed breed

with one of these three breeds as the major component. These DNA samples have been set aside for use in future case-control studies designed to identify haplotypes associated with specific traits key to their purpose.

In Year 3 we met with a panel of key opinion leaders in the canine genetics community to contribute to the design of a new higher density SNP set. The goal of this new higher density (HD) platform was to provide an improved means to generate genome wide association data for more complex traits, such as behavior. Through several discussion among the group, we selected 1,104,936 high quality SNPs from over 19,000,000 SNPs that had been identified from over 350 whole canine genome sequences. The SNPs selected were those with the highest level of polymorphism across numerous dog breeds, including breeds that are primary contributors to the MWD population. With a SNP located every 2,200 bp across the entire canine genome, this new set offers 6x the density of the initial design, while simultaneously increasing the number of informative SNPs across breeds from ~55% to ~85%. In short, this new canine SNP set has the potential to provide a substantially greater ability to detect genetic variants associated with complex traits.

The implementation of this new canine HD-design will require funding beyond the current award. At this time the additional funding needed will be used to demonstrate the efficacy of this new genetics platform. We anticipate that these fund will be provided by consortium members. It is expected that access to this new SNP-platform will be made broadly available to canine genetic researchers with the expectation that data will be shared as a means to validate the utility of this new design.